stockportfolio.pro
Mesoblast Limited (MESO)
Healthcare · Biotechnology · NasdaqGS
Mesoblast Limited revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $10.21M | $7.50M | $5.90M | $17.20M |
| Gross profit | — | $7.50M | $5.90M | $12.07M |
| Net income | $-91.35M | $-81.89M | $-87.96M | $-102.14M |
| Net margin | -894.6% | -1091.7% | -1490.3% | -593.9% |
Source: Mesoblast Limited SEC filings (10-K).
Explore 4 years of Mesoblast Limited financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MESO in your portfolio →
Mesoblast Limited financial history by metric
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Mesoblast Limited — frequently asked questions
What is Mesoblast Limited's revenue?
Mesoblast Limited (MESO) reported revenue of $17.20M for fiscal year 2025, up 191.4% from the prior year, according to its SEC filings.
Is Mesoblast Limited profitable?
No — MESO reported a net loss of $-102.14M in fiscal 2025.
What is MESO's P/E ratio?
Mesoblast Limited trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Mesoblast Limited growing?
MESO's revenue grew at roughly 19.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Mesoblast Limited have?
As of fiscal year 2025, MESO carried roughly $121.89M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Mesoblast Limited's gross margin?
MESO's gross margin was 70.2% in fiscal 2025 — gross profit of $12.07M on revenue of $17.20M.
What is Mesoblast Limited's market cap?
Mesoblast Limited (MESO) has a market capitalization of about $1.79B, based on the latest data in our nightly-refreshed cache.
When does Mesoblast Limited's fiscal year end?
MESO's fiscal year ends in June. Its most recent annual filing covers the fiscal year ending 2025-06-30.
Where does this data come from?
All figures are computed from Mesoblast Limited's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.